Financial Statements Notes to the Company Financial Statements 1 Fixed asset investments Investments in subsidiaries Shares Loans Total $m $m $m At 1 January 2016 16,053 13,994 30,047 Additions 2,480 2,480 Transfer to current assets 1,749 1,749 Capital reimbursement 27 27 Exchange 307 307 Amortisation 55 At 31December 2016 16,026 14,423 30,449 A list of subsidiaries is included on pages193 to 196.
2 Non-trade creditors 2016 2015 $m $m Amounts due within one year Short-term borrowings 371 679 Other creditors 140 128 Amounts owed to Group undertakings 7 7 518 814 3 Loans Repayment 2016 2015 dates $m $m Amounts due within one year Interest-bearing loans and borrowings unsecured 5.9% Callable bond US dollars 2017 1,749 1,749 Amounts due after more than one year Amounts owed to Group undertakings unsecured 7.2% Loan US dollars 2023 283 283 Interest-bearing loans and borrowings unsecured 5.9% Callable bond US dollars 2017 1,747 Floating rate notes US dollars 2018 399 399 1.75% Callable bond US dollars 2018 998 997 1.95% Callable bond US dollars 2019 998 997 2.375% Callable bond US dollars 2020 1,589 1,586 0.875% Non-callable bond euros 2021 782 812 0.25% Callable bond euros 2021 522 0.75% Callable bond euros 2024 937 3.375% Callable bond US dollars 2025 1,976 1,971 1.25% Callable bond euros 2028 827 5.75% Non-callable bond pounds sterling 2031 426 515 6.45% Callable bond US dollars 2037 2,719 2,719 4% Callable bond US dollars 2042 986 986 4.375% Callable bond US dollars 2045 979 976 14,138 13,705 2016 2015 $m $m Loans or instalments thereof are repayable: After five years from balance sheet date 9,133 8,262 From two to five years 3,891 3,979 From one to two years 1,397 1,747 Within one year 1,749 Total unsecured 16,170 13,988 With the exception of the 2018 floating rate notes, all loans are at fixed interest rates.
Accordingly, the fair values of the loans will change as market rates change.
However, since the loans are held at amortised cost, changes in interest rates and the credit rating of the Company do not have any effect on the Companys net assets.
AstraZeneca Annual Report and Form 20-F Information 2016 201 Financial Statements 4 Share capital Details of share capital movements in the year and share option schemes are included in Note22 to the Group Financial Statements.
5 Contingent liabilities In addition to the matter disclosed below, there are other cases where the Company is named as a party to legal proceedings.
These include the Nexium and Farxiga product liability litigations, each of which are described more fully in Note28 to the Group Financial Statements.
Foreign Corrupt Practices Act In connection with investigations into anti-bribery and corruption issues in the pharmaceutical industry, AstraZeneca has received inquiries from enforcement agencies, including the DOJ and the SEC, regarding, among other things, sales practices, internal controls, certain distributors and interactions with healthcare providers and other government officials in several countries.
In August 2016, AstraZeneca entered into a civil settlement with the SEC to resolve these inquiries.
The DOJ has informed AstraZeneca that it has closed its inquiry into this matter.
Other The Company has guaranteed the external borrowing of a subsidiary in the amount of $286m.
6 Statutory and other information The Directors were paid by another Group company in 2016 and 2015.
7 Subsequent events On 31January 2017, the Company received a dividend from a subsidiary of $1,623m.
202 AstraZeneca Annual Report and Form 20-F Information 2016
